Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer?

Απλή σελίδα τεκμηρίου
dc.contributor.authorHofmockel, G.en
dc.contributor.authorBassukas, I. D.en
dc.contributor.authorWittmann, A.en
dc.contributor.authorDammrich, J.en
dc.date.accessioned2015-11-24T19:08:49Z
dc.date.available2015-11-24T19:08:49Z
dc.identifier.issn0007-1331-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20599
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectCarcinoma, Renal Cell/*metabolism/pathology/surgeryen
dc.subjectDisease-Free Survivalen
dc.subjectDrug Resistance, Multiple/*geneticsen
dc.subject*Genes, MDRen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectKidney Neoplasms/*metabolism/pathology/surgeryen
dc.subjectMiddle Ageden
dc.subjectMultivariate Analysisen
dc.subjectNeoplasm Stagingen
dc.subjectNephrectomy/mortalityen
dc.subjectRetrospective Studiesen
dc.subjectSurvival Analysisen
dc.subjectTreatment Outcomeen
dc.titleIs the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer?en
heal.abstractOBJECTIVE: To determine the significance of the expression of the multidrug resistance gene product (MDR-1) for the aggressiveness of renal cell carcinoma (RCC). PATIENTS AND METHODS: The study comprised 31 patients with clinically locally confined RCC treated with radical nephrectomy (mean age 64.1 years, range 41-78; mean follow-up 5.4 years, range 4.3-7.3). Their survival time and disease-free period were evaluated retrospectively. The expression of the MDR-1 gene product was determined immunohistochemically using the JSB-1 antibody in formalin-fixed paraffin-embedded tumour samples from these patients. The significance of this variable and tumour stage and malignancy grade was assessed for predicting the survival and disease-free period using Kaplan-Meier plots (log-rank test or Tarone's test) and the Cox multiple hazard regression analysis. RESULTS: In a univariate analysis, tumour stage (P < 0.002), malignancy grade (P < 0.007) and MDR-1 (P < 0.03) were significant prognostic variables for both survival and disease-free period. Lower MDR-1 expression was correlated with poorer prognosis. On multivariate analysis, MDR-1 and tumour stage were significant factors for predicting the disease-free period, whereas tumour stage and malignancy grade were the most relevant factors for survival time. Calculating prognostic indices based on the results of the Cox analysis, MDR-1 could replace malignancy grade, resulting in a better prediction of survival and disease-free period (P < 0.001 vs 0.0031, P < 0.001 vs 0.021, respectively). CONCLUSION: MDR-1, an established predictor for chemo-resistance, may also be a potent prognostic factor for outcome in patients with locally confined RCC. Moreover, MDR-1 expression seems to correlate with the differentiation of the RCC and thus its value as an objective measure of the degree of differentiation should be further explored.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9240173-
heal.journalNameBr J Urolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1997-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ